aTYR PHARMA INC (ATYR) Form 10-Q — Aug 7, 2026
aTyr Pharma reported a Q2 2026 net loss of $10.3 million, roughly half the $19.5 million loss a year earlier, with R&D expense falling to $6.7 million from $15.4 million after the EFZO-FIT Phase 3 study was completed in September 2025. On August 7, 2026 the board approved a Restructuring Plan that cuts the workforce by approximately 60% to 20 full-time employees, expected to reduce annualized operating expenses by about $13 million beginning in Q4 2026, with roughly $4.2 million in severance-related charges to be booked in Q3 2026.
Key figures
- Cash Position
- 58900000
- Shares Outstanding
- 98087425
- Q2 2026 eps
- -0.11
- Q2 ga expense
- 4133000
- Q2 rnd expense
- 6748000
- Restricted cash
- 1495000
- Q2 2025 net loss
- 19532000
- Q2 2026 net loss
- 10310000
- Six month 2026 eps
- -0.22
- Accumulated deficit
- 627264000
- Efzo fit enrollment
- 268
- Workforce reduction
- ~60% to 20 full-time employees
- Atm program capacity
- 215000000
- Cash and equivalents
- 16160000
- Six month 2025 net loss
- 34413000
- Six month 2026 net loss
- 21102000
- Severance payment window
- August 2026 to September 2027
- Q2 rnd expense prior year
- 15384000
- Planned phase 3 enrollment
- 372
- Available for sale investments
- 41258000
- Restructuring charges estimate
- 4200000
- Annualized opex savings estimate
- 13000000
Price after filing
Close on the filing date to close N calendar days later (from $0.53). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.